QQQ   425.84 (-1.22%)
AAPL   168.00 (-0.81%)
MSFT   411.84 (-0.66%)
META   494.17 (-1.12%)
GOOGL   155.47 (+0.69%)
AMZN   181.28 (-1.11%)
TSLA   155.45 (-1.06%)
NVDA   840.35 (-3.87%)
AMD   154.02 (-5.78%)
NIO   3.91 (+2.62%)
BABA   68.82 (-1.13%)
T   16.12 (+0.19%)
F   12.04 (-0.41%)
MU   116.33 (-4.47%)
GE   155.67 (-0.70%)
CGC   6.49 (-3.13%)
DIS   112.94 (-0.83%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.26 (-0.27%)
XOM   118.63 (-0.05%)
QQQ   425.84 (-1.22%)
AAPL   168.00 (-0.81%)
MSFT   411.84 (-0.66%)
META   494.17 (-1.12%)
GOOGL   155.47 (+0.69%)
AMZN   181.28 (-1.11%)
TSLA   155.45 (-1.06%)
NVDA   840.35 (-3.87%)
AMD   154.02 (-5.78%)
NIO   3.91 (+2.62%)
BABA   68.82 (-1.13%)
T   16.12 (+0.19%)
F   12.04 (-0.41%)
MU   116.33 (-4.47%)
GE   155.67 (-0.70%)
CGC   6.49 (-3.13%)
DIS   112.94 (-0.83%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.26 (-0.27%)
XOM   118.63 (-0.05%)
QQQ   425.84 (-1.22%)
AAPL   168.00 (-0.81%)
MSFT   411.84 (-0.66%)
META   494.17 (-1.12%)
GOOGL   155.47 (+0.69%)
AMZN   181.28 (-1.11%)
TSLA   155.45 (-1.06%)
NVDA   840.35 (-3.87%)
AMD   154.02 (-5.78%)
NIO   3.91 (+2.62%)
BABA   68.82 (-1.13%)
T   16.12 (+0.19%)
F   12.04 (-0.41%)
MU   116.33 (-4.47%)
GE   155.67 (-0.70%)
CGC   6.49 (-3.13%)
DIS   112.94 (-0.83%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.26 (-0.27%)
XOM   118.63 (-0.05%)
QQQ   425.84 (-1.22%)
AAPL   168.00 (-0.81%)
MSFT   411.84 (-0.66%)
META   494.17 (-1.12%)
GOOGL   155.47 (+0.69%)
AMZN   181.28 (-1.11%)
TSLA   155.45 (-1.06%)
NVDA   840.35 (-3.87%)
AMD   154.02 (-5.78%)
NIO   3.91 (+2.62%)
BABA   68.82 (-1.13%)
T   16.12 (+0.19%)
F   12.04 (-0.41%)
MU   116.33 (-4.47%)
GE   155.67 (-0.70%)
CGC   6.49 (-3.13%)
DIS   112.94 (-0.83%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.26 (-0.27%)
XOM   118.63 (-0.05%)
NASDAQ:VINC

Vincerx Pharma (VINC) Stock Price, News & Analysis

$0.95
+0.01 (+1.12%)
(As of 04:28 PM ET)
Today's Range
$0.91
$0.98
50-Day Range
$0.87
$8.06
52-Week Range
$0.61
$9.37
Volume
353,582 shs
Average Volume
1.32 million shs
Market Capitalization
$20.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Vincerx Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
442.0% Upside
$5.00 Price Target
Short Interest
Healthy
5.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.02mentions of Vincerx Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.97) to ($1.11) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.20 out of 5 stars

Medical Sector

521st out of 914 stocks

Pharmaceutical Preparations Industry

230th out of 412 stocks

VINC stock logo

About Vincerx Pharma Stock (NASDAQ:VINC)

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

VINC Stock Price History

VINC Stock News Headlines

Don’t expose yourself to stocks during the week
The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.
The Rise of Zyn: The Oral Nicotine Product Going Viral
Vincerx Pharma Inc (VINC) Gets a Buy from Leerink Partners
Don’t expose yourself to stocks during the week
The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.
Why Is Vincerx Pharma (VINC) Stock Down 64% Today?
Vincerx Pharma Inc
Vincerx Pharma Inc Ordinary Shares VINC
See More Headlines
Receive VINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/12/2021
Today
4/17/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VINC
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+440.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-40,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.52 per share

Miscellaneous

Free Float
17,002,000
Market Cap
$19.79 million
Optionable
Not Optionable
Beta
1.10
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives


VINC Stock Analysis - Frequently Asked Questions

Should I buy or sell Vincerx Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VINC shares.
View VINC analyst ratings
or view top-rated stocks.

What is Vincerx Pharma's stock price target for 2024?

1 Wall Street research analysts have issued 12-month target prices for Vincerx Pharma's shares. Their VINC share price targets range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 442.0% from the stock's current price.
View analysts price targets for VINC
or view top-rated stocks among Wall Street analysts.

How have VINC shares performed in 2024?

Vincerx Pharma's stock was trading at $1.18 at the beginning of 2024. Since then, VINC shares have decreased by 21.8% and is now trading at $0.9225.
View the best growth stocks for 2024 here
.

When is Vincerx Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VINC earnings forecast
.

How were Vincerx Pharma's earnings last quarter?

Vincerx Pharma, Inc. (NASDAQ:VINC) announced its earnings results on Thursday, August, 12th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.18.

How do I buy shares of Vincerx Pharma?

Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VINC) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners